Published in Oncotarget on January 01, 2013
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget (2014) 1.11
PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res (2013) 1.11
Geroconversion: irreversible step to cellular senescence. Cell Cycle (2014) 1.07
The structural basis for cancer treatment decisions. Oncotarget (2014) 1.05
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget (2014) 0.95
AKT in cancer: new molecular insights and advances in drug development. Br J Clin Pharmacol (2016) 0.90
Mutant AKT1-E17K is oncogenic in lung epithelial cells. Oncotarget (2015) 0.85
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget (2015) 0.80
AKT signaling in ERBB2-amplified breast cancer. Pharmacol Ther (2015) 0.80
HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A (2015) 0.79
A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics (2014) 0.78
Proteome-Scale Investigation of Protein Allosteric Regulation Perturbed by Somatic Mutations in 7,000 Cancer Genomes. Am J Hum Genet (2016) 0.77
Significance of persistent inflammation in respiratory disorders induced by nanoparticles. J Immunol Res (2014) 0.77
AKT1E17K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer. PLoS One (2016) 0.77
Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Oncotarget (2016) 0.76
A Hot-spot of In-frame Duplications Activates the Oncoprotein AKT1 in Juvenile Granulosa Cell Tumors. EBioMedicine (2015) 0.76
Protein mislocalization: mechanisms, functions and clinical applications in cancer. Biochim Biophys Acta (2014) 0.76
A network-based method to evaluate quality of reproducibility of differential expression in cancer genomics studies. Oncotarget (2015) 0.75
Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Sci Rep (2017) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 10.98
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. Breast Cancer Res Treat (2007) 2.49
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood (2008) 1.64
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res (2009) 1.41
Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry (2008) 1.30
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A (2012) 1.22
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations. Oncogene (2010) 1.16
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer (2012) 0.95
NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell (2011) 2.27
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci U S A (2011) 2.12
Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proc Natl Acad Sci U S A (2009) 2.02
Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res (2007) 1.63
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood (2007) 1.60
A conserved transcriptional enhancer regulates RAG gene expression in developing B cells. Immunity (2003) 1.50
PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biol Ther (2011) 1.44
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A (2007) 1.22
A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targeting. Nat Protoc (2007) 1.13
PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. Clin Cancer Res (2013) 1.11
The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res (2012) 1.07
Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res (2013) 1.00
P21 gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biol Ther (2007) 0.95
Vesicle--biopolymer gels: networks of surfactant vesicles connected by associating biopolymers. Langmuir (2005) 0.84
Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity. Oncotarget (2016) 0.76
Engineering targeted chromosomal amplifications in human breast epithelial cells. Breast Cancer Res Treat (2015) 0.75
TORn in Two Over Breast Cancer Drug Resistance. Oncology (Williston Park) (2013) 0.75